Skip to main content
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · XENE ISIN · CA98420N1050 LEI · 549300XV44Q9Z1MIPQ03 US Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2023-11-30 Capital/Financing Update
Country CA Canada
Listing US XENE

About Xenon Pharmaceuticals Inc.

https://www.xenon-pharma.com/

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to the discovery, clinical development, and commercialization of therapeutics for neurological and psychiatric disorders. The company leverages its expertise in human genetics and a deep understanding of ion channel biology to develop medicines that modulate ion channels, targeting the central and peripheral nervous systems. Its late-stage pipeline includes azetukalner, an investigational candidate being developed for the treatment of epilepsy and depression.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 29, 2023, by Xenon Pharmaceuticals Inc. It details the entry into a material definitive agreement related to an underwritten public offering of common shares and pre-funded warrants. The document includes descriptions of the underwriting agreement, terms of the offering, and related exhibits such as the underwriting agreement, warrant form, and legal opinion. There are no financial statements or detailed financial performance data included, nor is this a transcript, annual or quarterly report, or governance document. The content focuses on a capital raising event and financing terms. Therefore, this filing is best classified as a Capital/Financing Update (CAP). The document length (9059 characters) supports it being a full filing rather than a brief announcement. Confidence is high given the clear description of a financing transaction and underwriting agreement.
2023-11-30 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act of 1933, related to an offering of common shares and pre-funded warrants by Xenon Pharmaceuticals Inc. It includes detailed information about the offering terms, underwriting, risk factors, use of proceeds, and other related disclosures typical of a securities offering document. The presence of registration numbers, references to the Securities and Exchange Commission, and detailed offering terms indicate this is a capital raising document. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is lengthy (15,000 characters) and contains substantive information about the offering, not merely an announcement or a brief summary, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). Therefore, the correct classification is CAP with high confidence.
2023-11-29 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 27, 2023. It announces the issuance of a press release regarding topline results from a Phase 2 clinical trial. The document includes no financial statements or detailed financial data but references an attached press release as Exhibit 99.1. The length is 3345 characters, which is relatively short and consistent with an announcement rather than a full report. The content is primarily an event announcement and press release attachment, not a detailed financial or management report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-11-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated November 9, 2023. It announces a press release regarding a clinical trial result failure by a partner company. The document includes a press release as an exhibit but does not contain financial statements or detailed financial data. The length is 3303 characters, which is relatively short and consistent with an announcement rather than a full report. The content is an event disclosure rather than a financial report, earnings release, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-11-09 English
10-Q
Interim / Quarterly Report Q3 2023
2023-11-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The text specifically mentions that the company announced its financial results for the three and nine months ended September 30, 2023, via a press release attached as an exhibit. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release. The length of the document is 4468 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. According to the rules, if a document is short and announces or attaches a report (like a press release of financial results), it should be classified as a Regulatory Filing (RNS) rather than an Interim Report (IR) or Earnings Release (ER). The document is not a transcript, proxy, or other specific filing type. Therefore, the best classification is Regulatory Filings (RNS).
2023-11-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.